baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ARGENX SE/ NL0010832176 /

- -	Chg. -	Volume	Bid03:01:05	Ask03:01:05	Market Capitalization	Dividend Y.	P/E Ratio
344.90EUR	-	- Turnover: -	-Bid Size: -	-Ask Size: -	20.38 bill.EUR	-	-

GlobeNewswire 09/05 argenx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 07/05 argenx announces results of Annual General Meeting of Shareholders

GlobeNewswire 07/05 argenx to Present at BofA Securities 2024 Health Care Conference

GlobeNewswire 02/05 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

GlobeNewswire 16/04 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...

GlobeNewswire 27/03 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

GlobeNewswire 26/03 argenx Announces Annual General Meeting of Shareholders on May 7, 2024

GlobeNewswire 26/03 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...

GlobeNewswire 07/03 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...

GlobeNewswire 29/02 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire 26/02 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 22/02 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...

GlobeNewswire 20/02 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...

GlobeNewswire 14/02 Genmab Publishes 2023 Annual Report

GlobeNewswire 18/01 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcu...

GlobeNewswire 08/01 argenx Highlights 2024 Strategic Priorities

GlobeNewswire 02/01 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 07/12/2023 TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...

GlobeNewswire 28/11/2023 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocyt...

GlobeNewswire 16/11/2023 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Gene...

GlobeNewswire 13/11/2023 RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire 09/11/2023 X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

GlobeNewswire 07/11/2023 Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

GlobeNewswire 01/11/2023 RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

GlobeNewswire 01/11/2023 argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scie...

ARGENX SE/ NL0010832176 /

If you wish to receive reply to your feedback, please provide your email address.